Interstitial macrophages are a focus of viral takeover and inflammation in COVID-19 initiation in human lung

在人类肺部 COVID-19 感染初期,间质巨噬细胞是病毒侵袭和炎症的中心。

阅读:2
作者:Timothy Ting-Hsuan Wu #,Kyle J Travaglini #,Arjun Rustagi #,Duo Xu,Yue Zhang ,Leonid Andronov,SoRi Jang,Astrid Gillich,Roozbeh Dehghannasiri,Giovanny J Martínez-Colón,Aimee Beck,Daniel Dan Liu,Aaron J Wilk,Maurizio Morri,Winston L Trope,Rob Bierman,Irving L Weissman,Joseph B Shrager,Stephen R Quake,Christin S Kuo,Julia Salzman,W E Moerner,Peter S Kim ,Catherine A Blish ,Mark A Krasnow

Abstract

Early stages of deadly respiratory diseases including COVID-19 are challenging to elucidate in humans. Here, we define cellular tropism and transcriptomic effects of SARS-CoV-2 virus by productively infecting healthy human lung tissue and using scRNA-seq to reconstruct the transcriptional program in "infection pseudotime" for individual lung cell types. SARS-CoV-2 predominantly infected activated interstitial macrophages (IMs), which can accumulate thousands of viral RNA molecules, taking over 60% of the cell transcriptome and forming dense viral RNA bodies while inducing host profibrotic (TGFB1, SPP1) and inflammatory (early interferon response, CCL2/7/8/13, CXCL10, and IL6/10) programs and destroying host cell architecture. Infected alveolar macrophages (AMs) showed none of these extreme responses. Spike-dependent viral entry into AMs used ACE2 and Sialoadhesin/CD169, whereas IM entry used DC-SIGN/CD209. These results identify activated IMs as a prominent site of viral takeover, the focus of inflammation and fibrosis, and suggest targeting CD209 to prevent early pathology in COVID-19 pneumonia. This approach can be generalized to any human lung infection and to evaluate therapeutics.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。